NiKang Therapeutics
Latest round
- Series C
Last raised
- May 2021
Total raised
- $260M
Investors
- 22
About NiKang Therapeutics
NiKang Therapeutics, Inc.Founded in 2017, NiKang Therapeutics, Inc. is headquartered in Wilmington, US, and specializes in the development of small molecule drugs targeting oncology challenges. The company has successfully completed 3 deals to date, with the most recent deal occurring on May 19, 2021. Zhenhai Gao, one of the founders, serves as the current CEO.NiKang Therapeutics specializes in developing innovative small molecule drugs for oncology treatment. Its core product candidates include NKT2173, NKT2152, and NKT3964, targeting SHP2, HIF2a, and CDK2, respectively.NiKang Therapeutics generates revenue through strategic partnerships and collaborations with major pharmaceutical companies, as well as clinical development agreements for its drug candidates. The company's business model is predominantly B2B, allowing for shared resources and market access. The company aims to explore new markets to enhance its reach, with a focus on geographic regions that are underserved in terms of advanced cancer therapies.
Who invested in NiKang Therapeutics
22 investors across 3 rounds
See all investors in NiKang Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about NiKang Therapeutics
Who invested in NiKang Therapeutics?
NiKang Therapeutics has 22 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has NiKang Therapeutics raised?
NiKang Therapeutics has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did NiKang Therapeutics last raise money?
NiKang Therapeutics's most recent round on record is a Series C, in May 2021.
What does NiKang Therapeutics do?
NiKang Therapeutics is a biotechnology company.
Where is NiKang Therapeutics headquartered?
NiKang Therapeutics is headquartered in Wilmington, US.
Which VCs invest in companies like NiKang Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at NiKang Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like NiKang Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.